Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Journal of the Optical Society of America. A, Optics, Image Science, and Vision
|
November 3, 2007
Modeling liquid-crystal gradient-index lenses
T C Kraan, T van Bommel, R A M Hikmet
Journal of Immunology (Baltimore, Md. : 1950)
|
April 14, 1999
Lipopolysaccharide-coated erythrocytes activate human neutrophils via CD14 while subsequent binding is through CD11b/CD18
A Troelstra, L A de Graaf-Miltenburg, T van Bommel, et al.
Infection and Immunity
|
March 18, 2000
Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation
C J de Haas, E M van Leeuwen, T van Bommel, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
September 1, 2009
The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test
H J M Jagt, M L E Bekkers, S A J T van Bommel, et al.
Antimicrobial Agents and Chemotherapy
|
October 1, 1996
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
C A Boucher, W Keulen, T van Bommel, et al.
Antimicrobial Agents and Chemotherapy
|
July 1, 1995
Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor
M Reedijk, C A Boucher, T van Bommel, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Journal of the Optical Society of America. A, Optics, Image Science, and Vision
|
November 3, 2007
Modeling liquid-crystal gradient-index lenses
T C Kraan, T van Bommel, R A M Hikmet
Journal of Immunology (Baltimore, Md. : 1950)
|
April 14, 1999
Lipopolysaccharide-coated erythrocytes activate human neutrophils via CD14 while subsequent binding is through CD11b/CD18
A Troelstra, L A de Graaf-Miltenburg, T van Bommel, et al.
Infection and Immunity
|
March 18, 2000
Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation
C J de Haas, E M van Leeuwen, T van Bommel, et al.
Biologicals : Journal of the International Association of Biological Standardization
|
September 1, 2009
The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test
H J M Jagt, M L E Bekkers, S A J T van Bommel, et al.
Antimicrobial Agents and Chemotherapy
|
October 1, 1996
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
C A Boucher, W Keulen, T van Bommel, et al.
Antimicrobial Agents and Chemotherapy
|
July 1, 1995
Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor
M Reedijk, C A Boucher, T van Bommel, et al.
Page
of 1